Aprile 25, 2024

Efficacia del vaccino del vaccino ricombinante contro la malattia di Marek 301B / 1 Espressione dell’interleuchina-15 di pollo

Per controllare la coccidiosi nei polli sono necessari vaccini orali economici e facili da produrre per ridurre l’impatto della malattia sul benessere e sulla performance economica.  Il lievito Saccharomyces cerevisiae   che esprime i tre  antigeni di Eimeria tenella   è stato sviluppato e fornito ai polli sotto forma di vaccini orali di lievito intero liofilizzati e uccisi con il calore in quattro studi separati. Dopo la vaccinazione, la  replicazione di E. tenella   è stata ridotta dopo il challenge a basse dosi (250 oocisti) nelle galline ovaiole Hy-Line Brown (p <0,01). Allo stesso modo, il punteggio per le lesioni nel cieco è stato ridotto nei polli Hy-Line Brown di galline ovaiole inoculati con una miscela di S. cerevisiae esprimente EtAMA1, EtIMP1 ed EtMIC3 dopo challenge a livello patogeno (4000  E. tenella oocisti   ; p <0,01 ).

L’aumento di peso medio dopo il challenge di 15.000  oocisti di E. tenella   era significativamente aumentato nei polli da carne vaccinati Cobb500 rispetto ai controlli vaccinati fittizia (p <0,01). 

  • Pertanto, i vaccini ricombinanti inattivati ​​per lievito offrono capacità di controllo della coccidiosi economicamente vantaggiose e scalabili importanti per la produzione di polli da carne e polli allevati nei paesi a basso e medio reddito (LMIC).
  • Il sottotipo H5 del virus dell’influenza aviaria ad alta patogenicità (HPAIV) è stato introdotto in Corea del Sud ogni 2 o 3 anni   dagli   uccelli acquatici migratori selvatici, causando danni devastanti all’industria del pollame. Mentre la maggior parte dei danni causati dall’HPAIV e della perdita economica si concentra sulle galline ovaiole, è noto che le anatre domestiche svolgono un ruolo importante nella trasmissione da fattoria a fattoria.
  • Tuttavia, la maggior parte degli studi sui vaccini HPAIV nel pollame sono stati condotti con vaccini in emulsione oleosa inattivata. In questo studio, abbiamo sviluppato un vaccino vettore ricombinante vivo del virus della malattia di Newcastle (NDV) contro HPAIV H5 (rK148 / ES2-HA) utilizzando un ceppo vaccinale NDV precedentemente stabilito (K148 / 08) isolato dall’anatra selvatica.
  •  L’efficacia del     vaccino oronasale o spray è stata valutata contro l’infezione letale da HPAIV H5 in anatre e polli domestici  L’inoculazione oculonasale di rK148 / ES2-HA nei polli e nelle anatre ha indotto titoli anticorpali anti-HPAIV già 1 o 2 settimane dopo una singola dose di vaccinazione, mentre la vaccinazione spray nelle anatre ha indotto anticorpi anti-HPAIV dopo la vaccinazione di richiamo.
  • Polli e anatre vaccinati con rK148 / ES2-HA hanno mostrato alti tassi di sopravvivenza e bassa diffusione virale dopo la sfida con HPAIV H5N6. Nel complesso, la vaccinazione rK148 / ES2-HA ha prevenuto l’infezione fatale e ridotto la diffusione virale sia nei polli che nelle anatre. 
  • Il vaccino sviluppato in questo studio può essere utile per sopprimere la diffusione virale nelle epidemie di HPAIV H5, con facilità di applicazione del vaccino e rapida insorgenza dell’immunità.

Negli ultimi decenni, le malattie correlate all’adenovirus del pollame (FAdV) sono diventate un problema crescente per l’industria avicola in tutto il mondo.

Diverse strategie di immunizzazione contro FAdV sono state sperimentalmente testate, con particolare enfasi sui vaccini subunità contro la sindrome di epatite e idrocardio (HHS) causata da FAdV sierotipo 4 e l’epatite da inclusione (IBH) causata dai sierotipi 2, 8a, 8b e 11.
In questo studio, abbiamo esteso il nostro concetto innovativo di proteine ​​fibrose chimeriche ricombinanti per progettare una nuova chimera che combina epitopi di due diversi sierotipi, FAdV-4 e -11, e ne abbiamo studiato l’efficacia nella protezione simultanea dei polli contro HHS e IBH. Specifici polli privi di agenti patogeni sono stati inoculati con la nuova fibra chimerica ricombinante e quindi sfidati con il ceppo che ha causato HHS o IBH. Gli uccelli vaccinati / challenge hanno mostrato segni clinici ridotti, ridotta epatomegalia e livelli di AST inferiori rispetto ai corrispondenti controlli challenge.
Inoltre, il vaccino ha impedito l’atrofia degli organi linfoidi affetti da HHS come il timo e la capsula di Fabrizius e la carica virale negli organi bersaglio è stata significativamente ridotta. La protezione clinica è stata associata a livelli elevati di anticorpi contro il challenge misurati su piastre ELISA rivestite con antigene del vaccino. È interessante notare che lo sviluppo di anticorpi neutralizzanti era limitato contro FAdV-11 e assente contro FAdV-4, indicando che la protezione fornita da tale antigene può essere correlata a vari percorsi di immunizzazione.
In conclusione, abbiamo dimostrato che il concetto di vaccini con fibre chimeriche può essere esteso oltre i confini delle specie virali e rappresenta il primo vaccino a subunità FAdV a componente singolo a fornire una protezione completa contro varie malattie correlate a FAdV.

Il vaccino contro la malattia di Marek (MD) non fornisce un’immunità sterilizzante che impedirà la successiva replicazione e diffusione dell’MDV (MDV) negli uccelli vaccinati. 

È stato ipotizzato che l’immunità cellulare sia fondamentale per controllare la replicazione virale nei polli  poiché l’MDV si verifica nelle forme associate alla cellula ospite. Per migliorare l’efficacia del vaccino MD, in particolare l’immunità cellulare, abbiamo costruito un vaccino ricombinante v301B / 1-IL-15, MDV sierotipo 2 ceppo 301B / 1 che esprime l’interleuchina di pollo  (IL-15), una citochina che promuove i linfociti T proliferazione e migliora la risposta cellulare T.
Abbiamo testato l’efficacia del vaccino v301B / 1-IL-15 somministrato come vaccino MD bivalente in combinazione con l’herpesvirus del tacchino (HVT) contro una sfida altamente virulenta con MDV. L’espressione di IL-15 non ha influenzato la stabilità del virus e la crescita del ricombinante v301B / 1-IL-15.
Tuttavia, l’efficacia protettiva di v301B/1-IL-15 non era significativamente diversa da quella di v301B/1, il virus genitore utilizzato per costruire v301B/1-IL-15. La diffusione del virus della sfida è stata leggermente ridotta il giorno 21 (16 giorni dopo la sfida) nel gruppo v301B / 1-IL-15 più HVT, senza differenze statisticamente significative rispetto al gruppo v301B / 1 più HVT ed è stata osservata atrofia timica che è meno grave nel gruppo vaccinato v301B / 1-IL-15 più HVT. Nel complesso, la protezione di v301B / 1-IL-15 non differiva da v301B / 1 contro una sfida altamente virulenta con MDV, ma non ha influenzato l’efficacia del vaccino MD bivalente.

Efficacia di un vaccino ricombinante contro la malattia di Marek 301B/1 che esprime l’interleuchina-15 di pollo.

La vaccinazione contro la malattia di Marek (MD) non fornisce l’immunità sterica per prevenire la successiva replicazione e diffusione di questo virus (MDV) negli uccelli vaccinati.
  • Si ipotizza che l’immunità cellulo-mediata sia essenziale per controllare replikacji wirusa w polli perché il virus e Marek istnieje w formach cell-associato nell’ospite. Per migliorare l’efficacia del  vaccino di Marek, in particolare dell’immunità cellulo-mediata, è stato costruito un virus ricombinante v301B/1-IL-15, che è un ceppo vaccinale del sierotipo 2, 301B/1, che esprime il gene per l’interleuchina-15 di pollo (IL-15)  , che è una citochina che promuove la proliferazione cellulare dei linfociti T e migliora la risposta dei linfociti T.
  • Guarda il test delle prestazioni dell’aspirapolvere v301B / 1-IL-15 somministrato insieme all’aspirapolvere bivalente enfermedad di Mark in combinazione con il virus dell’herpes virale (HVT) contro il desafío muy virulento. L’espressione di IL-15 non ha avuto alcun effetto sulla creazione del virus e sulla replicazione del virus ricombinante v301B / 1-IL-15. Sin embargo, la eficacia protector de v301B / 1-IL-15 no fue sia diverente de la obtenida con el virus v301B / 1, que es el virus progenitor utilizado para construir v301B / 1-IL-15.

Immunization Grade Mouse Type I Collagen, 5 mg, lyophilized

1066 Chondrex 5 mg 206 EUR

Immunization Grade Human Type XI Collagen, 1 mg, lyophilized

1085 Chondrex 1 mg 353 EUR

Immunization Grade Bovine Type I Collagen, 10 mg, lyophilized

1062 Chondrex 10 mg 152 EUR

Immunization Grade Rabbit Type I Collagen, 1 mg, lyophilized

1067 Chondrex 1 mg 87 EUR

Immunization Grade Canine Type I Collagen, 1 mg, lyophilized

1068 Chondrex 1 mg 87 EUR

Immunization Grade Human Type III Collagen, 1 mg, lyophilized

1305 Chondrex 1 mg 303 EUR

Immunization Grade Bovine Type IX Collagen, 5 mg, lyophilized

1072 Chondrex 5 mg 331 EUR

Immunization Grade Bovine Type XI Collagen, 5 mg, lyophilized

1082 Chondrex 5 mg 271 EUR

Immunization Grade Bovine Type III Collagen, 1 mg, lyophilized

1302 Chondrex 1 mg 147 EUR

Immunization Grade Porcine Type IX Collagen, 5 mg, lyophilized

1073 Chondrex 5 mg 331 EUR

Immunization Grade Porcine Type XI Collagen, 5 mg, lyophilized

1083 Chondrex 5 mg 271 EUR

Immunization Grade Human Amnion Type V Collagen, 1 mg, lyophilized

1095 Chondrex 1 mg 347 EUR

Immunization Grade Bovine Amnion Type V Collagen, 1 mg, lyophilized

1092 Chondrex 1 mg 303 EUR

Immunization Grade Human Placenta Type V Collagen, 1 mg, lyophilized

10951 Chondrex 1 mg 347 EUR

cBSA *Optimized for Maximum Immunization Response*

5600 AAT Bioquest 10 mg 227 EUR

cBSA *Optimized for Maximum Immunization Response*

5600-10mg AAT Bioquest 10 mg 222 EUR

hBSA *Optimized for Maximum Immunization Response*

5601-10mg AAT Bioquest 10 mg 222 EUR

cOVA *Optimized for Maximum Immunization Response*

5605 AAT Bioquest 10 mg 227 EUR

cOVA *Optimized for Maximum Immunization Response*

5605-10mg AAT Bioquest 10 mg 222 EUR

hOVA *Optimized for Maximum Immunization Response*

5606 AAT Bioquest 10 mg 227 EUR

hOVA *Optimized for Maximum Immunization Response*

5606-10mg AAT Bioquest 10 mg 222 EUR

Custom Production of Monoclonal antibodies (immunization, ELISA Kit, fusion, screening, Cloning of up to 3 clones)

MAB-1 Alpha Diagnostics 1 12483.6 EUR

CDCP1, CT (CDCP1, TRASK, CUB domain-containing protein 1, Membrane glycoprotein gp140, Subtractive immunization M plus HEp3-associated 135kD protein, Transmembrane and associated with src kinases, CD318)

MBS645296-02mL MyBiosource 0.2mL 695 EUR

CDCP1, CT (CDCP1, TRASK, CUB domain-containing protein 1, Membrane glycoprotein gp140, Subtractive immunization M plus HEp3-associated 135kD protein, Transmembrane and associated with src kinases, CD318)

MBS645296-5x02mL MyBiosource 5x0.2mL 2975 EUR

CDCP1, CT (CDCP1, TRASK, CUB domain-containing protein 1, Membrane glycoprotein gp140, Subtractive immunization M plus HEp3-associated 135kD protein, Transmembrane and associated with src kinases, CD318) (AP)

MBS6284050-02mL MyBiosource 0.2mL 980 EUR

CDCP1, CT (CDCP1, TRASK, CUB domain-containing protein 1, Membrane glycoprotein gp140, Subtractive immunization M plus HEp3-associated 135kD protein, Transmembrane and associated with src kinases, CD318) (AP)

MBS6284050-5x02mL MyBiosource 5x0.2mL 4250 EUR

CDCP1, CT (CDCP1, TRASK, CUB domain-containing protein 1, Membrane glycoprotein gp140, Subtractive immunization M plus HEp3-associated 135kD protein, Transmembrane and associated with src kinases, CD318) (PE)

MBS6284060-02mL MyBiosource 0.2mL 980 EUR

CDCP1, CT (CDCP1, TRASK, CUB domain-containing protein 1, Membrane glycoprotein gp140, Subtractive immunization M plus HEp3-associated 135kD protein, Transmembrane and associated with src kinases, CD318) (PE)

MBS6284060-5x02mL MyBiosource 5x0.2mL 4250 EUR

CDCP1, CT (CDCP1, TRASK, CUB domain-containing protein 1, Membrane glycoprotein gp140, Subtractive immunization M plus HEp3-associated 135kD protein, Transmembrane and associated with src kinases, CD318) (APC)

MBS6284051-02mL MyBiosource 0.2mL 980 EUR

CDCP1, CT (CDCP1, TRASK, CUB domain-containing protein 1, Membrane glycoprotein gp140, Subtractive immunization M plus HEp3-associated 135kD protein, Transmembrane and associated with src kinases, CD318) (APC)

MBS6284051-5x02mL MyBiosource 5x0.2mL 4250 EUR

CDCP1, CT (CDCP1, TRASK, CUB domain-containing protein 1, Membrane glycoprotein gp140, Subtractive immunization M plus HEp3-associated 135kD protein, Transmembrane and associated with src kinases, CD318) (Biotin)

MBS6284052-02mL MyBiosource 0.2mL 980 EUR

CDCP1, CT (CDCP1, TRASK, CUB domain-containing protein 1, Membrane glycoprotein gp140, Subtractive immunization M plus HEp3-associated 135kD protein, Transmembrane and associated with src kinases, CD318) (Biotin)

MBS6284052-5x02mL MyBiosource 5x0.2mL 4250 EUR

CDCP1, CT (CDCP1, TRASK, CUB domain-containing protein 1, Membrane glycoprotein gp140, Subtractive immunization M plus HEp3-associated 135kD protein, Transmembrane and associated with src kinases, CD318) (FITC)

MBS6284053-02mL MyBiosource 0.2mL 980 EUR

CDCP1, CT (CDCP1, TRASK, CUB domain-containing protein 1, Membrane glycoprotein gp140, Subtractive immunization M plus HEp3-associated 135kD protein, Transmembrane and associated with src kinases, CD318) (FITC)

MBS6284053-5x02mL MyBiosource 5x0.2mL 4250 EUR

CDCP1, CT (CDCP1, TRASK, CUB domain-containing protein 1, Membrane glycoprotein gp140, Subtractive immunization M plus HEp3-associated 135kD protein, Transmembrane and associated with src kinases, CD318) (MaxLight 405)

MBS6284055-01mL MyBiosource 0.1mL 980 EUR

CDCP1, CT (CDCP1, TRASK, CUB domain-containing protein 1, Membrane glycoprotein gp140, Subtractive immunization M plus HEp3-associated 135kD protein, Transmembrane and associated with src kinases, CD318) (MaxLight 405)

MBS6284055-5x01mL MyBiosource 5x0.1mL 4250 EUR

CDCP1, CT (CDCP1, TRASK, CUB domain-containing protein 1, Membrane glycoprotein gp140, Subtractive immunization M plus HEp3-associated 135kD protein, Transmembrane and associated with src kinases, CD318) (MaxLight 490)

MBS6284056-01mL MyBiosource 0.1mL 980 EUR

CDCP1, CT (CDCP1, TRASK, CUB domain-containing protein 1, Membrane glycoprotein gp140, Subtractive immunization M plus HEp3-associated 135kD protein, Transmembrane and associated with src kinases, CD318) (MaxLight 490)

MBS6284056-5x01mL MyBiosource 5x0.1mL 4250 EUR

CDCP1, CT (CDCP1, TRASK, CUB domain-containing protein 1, Membrane glycoprotein gp140, Subtractive immunization M plus HEp3-associated 135kD protein, Transmembrane and associated with src kinases, CD318) (MaxLight 550)

MBS6284057-01mL MyBiosource 0.1mL 980 EUR

CDCP1, CT (CDCP1, TRASK, CUB domain-containing protein 1, Membrane glycoprotein gp140, Subtractive immunization M plus HEp3-associated 135kD protein, Transmembrane and associated with src kinases, CD318) (MaxLight 550)

MBS6284057-5x01mL MyBiosource 5x0.1mL 4250 EUR

CDCP1, CT (CDCP1, TRASK, CUB domain-containing protein 1, Membrane glycoprotein gp140, Subtractive immunization M plus HEp3-associated 135kD protein, Transmembrane and associated with src kinases, CD318) (MaxLight 650)

MBS6284058-01mL MyBiosource 0.1mL 980 EUR

CDCP1, CT (CDCP1, TRASK, CUB domain-containing protein 1, Membrane glycoprotein gp140, Subtractive immunization M plus HEp3-associated 135kD protein, Transmembrane and associated with src kinases, CD318) (MaxLight 650)

MBS6284058-5x01mL MyBiosource 5x0.1mL 4250 EUR

CDCP1, CT (CDCP1, TRASK, CUB domain-containing protein 1, Membrane glycoprotein gp140, Subtractive immunization M plus HEp3-associated 135kD protein, Transmembrane and associated with src kinases, CD318) (MaxLight 750)

MBS6284059-01mL MyBiosource 0.1mL 980 EUR

CDCP1, CT (CDCP1, TRASK, CUB domain-containing protein 1, Membrane glycoprotein gp140, Subtractive immunization M plus HEp3-associated 135kD protein, Transmembrane and associated with src kinases, CD318) (MaxLight 750)

MBS6284059-5x01mL MyBiosource 5x0.1mL 4250 EUR

CDCP1, CT (CDCP1, TRASK, CUB domain-containing protein 1, Membrane glycoprotein gp140, Subtractive immunization M plus HEp3-associated 135kD protein, Transmembrane and associated with src kinases, CD318) (Azide free) (HRP)

MBS6284054-02mL MyBiosource 0.2mL 980 EUR

CDCP1, CT (CDCP1, TRASK, CUB domain-containing protein 1, Membrane glycoprotein gp140, Subtractive immunization M plus HEp3-associated 135kD protein, Transmembrane and associated with src kinases, CD318) (Azide free) (HRP)

MBS6284054-5x02mL MyBiosource 5x0.2mL 4250 EUR

CDCP1, isoform 1, CT (CUB domain containing protein 1, CD318, Membrane glycoprotein gp140, SIMA135, Subtractive immunization M plus HEp3-associated 135kD protein, Transmembrane and associated with src kinases, TRASK, UNQ2486/PRO5773)

MBS622157-01mg MyBiosource 0.1mg 655 EUR

CDCP1, isoform 1, CT (CUB domain containing protein 1, CD318, Membrane glycoprotein gp140, SIMA135, Subtractive immunization M plus HEp3-associated 135kD protein, Transmembrane and associated with src kinases, TRASK, UNQ2486/PRO5773)

MBS622157-5x01mg MyBiosource 5x0.1mg 2800 EUR

CDCP1, CT (CUB Domain Containing Protein 1, CD318, CD318 Antigen, FLJ13772, FLJ22375, FLJ22969, Membrane Glycoprotein gp140, MGC31813, Subtractive Immunization M Plus HEp3-associated 135kD Protein, Transmembrane and Associated with Src Kinases, TRASK)

MBS620721-01mg MyBiosource 0.1mg 810 EUR

CDCP1, CT (CUB Domain Containing Protein 1, CD318, CD318 Antigen, FLJ13772, FLJ22375, FLJ22969, Membrane Glycoprotein gp140, MGC31813, Subtractive Immunization M Plus HEp3-associated 135kD Protein, Transmembrane and Associated with Src Kinases, TRASK)

MBS620721-5x01mg MyBiosource 5x0.1mg 3500 EUR

T-Cell Grade Chick Type II Collagen, 0.5 mg, lyophilized

2021 Chondrex 0.5 mg 195 EUR

Lysozyme From Chicken Eggs (Food Grade)

LYZ-65E Creative BioMart 1g 39.2 EUR

Innovative Grade US Origin Chicken Bile

IGCHBILEF25ML Innovative research each 133 EUR

Innovative Grade US Origin Chicken Bile

IGCHBILEP100ML Innovative research each 320 EUR

Innovative Grade US Origin Chicken Bile

IGCHBILES100ML Innovative research each 320 EUR

Innovative Grade US Origin Chicken Bile

IGCHBILEZ25ML Innovative research each 133 EUR

Innovative Grade US Origin Chicken Foot

IGCHFTF Innovative research each 133 EUR

Innovative Grade US Origin Chicken Foot

IGCHFTP Innovative research each 210 EUR

Innovative Grade US Origin Chicken Foot

IGCHFTS Innovative research each 210 EUR

Innovative Grade US Origin Chicken Foot

IGCHFTZ Innovative research each 133 EUR

Innovative Grade US Origin Chicken Head

IGCHHDF Innovative research each 133 EUR

Innovative Grade US Origin Chicken Head

IGCHHDP Innovative research each 210 EUR

Innovative Grade US Origin Chicken Head

IGCHHDS Innovative research each 210 EUR

Innovative Grade US Origin Chicken Head

IGCHHDZ Innovative research each 133 EUR

Innovative Grade US Origin Chicken Aorta

IGCHAOFT1 Innovative research each 133 EUR

Innovative Grade US Origin Chicken Aorta

IGCHAOFT2 Innovative research each 133 EUR

Innovative Grade US Origin Chicken Aorta

IGCHAOPT1 Innovative research each 210 EUR

Innovative Grade US Origin Chicken Aorta

IGCHAOPT2 Innovative research each 210 EUR

Innovative Grade US Origin Chicken Aorta

IGCHAOST1 Innovative research each 210 EUR

Innovative Grade US Origin Chicken Aorta

IGCHAOST2 Innovative research each 210 EUR

Innovative Grade US Origin Chicken Aorta

IGCHAOZT1 Innovative research each 133 EUR

Innovative Grade US Origin Chicken Aorta

IGCHAOZT2 Innovative research each 133 EUR

Innovative Grade US Origin Chicken Heart

IGCHHTF Innovative research each 133 EUR

Innovative Grade US Origin Chicken Heart

IGCHHTP Innovative research each 210 EUR

Innovative Grade US Origin Chicken Heart

IGCHHTS Innovative research each 210 EUR

Innovative Grade US Origin Chicken Heart

IGCHHTZ Innovative research each 133 EUR

Innovative Grade US Origin Chicken Lungs

IGCHLGF Innovative research each 133 EUR

Innovative Grade US Origin Chicken Lungs

IGCHLGP Innovative research each 210 EUR

Innovative Grade US Origin Chicken Lungs

IGCHLGS Innovative research each 210 EUR

Innovative Grade US Origin Chicken Lungs

IGCHLGZ Innovative research each 133 EUR

Innovative Grade US Origin Chicken Liver

IGCHLRF1000GM Innovative research each 254 EUR

Innovative Grade US Origin Chicken Liver

IGCHLRF300GM Innovative research each 133 EUR

Innovative Grade US Origin Chicken Liver

IGCHLRP1000GM Innovative research each 330 EUR

Innovative Grade US Origin Chicken Liver

IGCHLRP300GM Innovative research each 210 EUR

Innovative Grade US Origin Chicken Liver

IGCHLRS1000GM Innovative research each 330 EUR

Innovative Grade US Origin Chicken Liver

IGCHLRS300GM Innovative research each 210 EUR

Innovative Grade US Origin Chicken Liver

IGCHLRZ1000GM Innovative research each 254 EUR

Innovative Grade US Origin Chicken Liver

IGCHLRZ300GM Innovative research each 133 EUR

Innovative Grade US Origin Chicken Serum

IGCHSER100ML Innovative research each 298 EUR

Innovative Grade US Origin Chicken Serum

IGCHSER50ML Innovative research each 185 EUR

Innovative Grade US Origin Chicken Plasma

IGCHPLAK2E100ML Innovative research each 298 EUR

Innovative Grade US Origin Chicken Plasma

IGCHPLAK2E50ML Innovative research each 185 EUR

Innovative Grade US Origin Chicken Plasma

IGCHPLAK3E100ML Innovative research each 298 EUR

Innovative Grade US Origin Chicken Plasma

IGCHPLAK3E50ML Innovative research each 185 EUR

Innovative Grade US Origin Chicken Plasma

IGCHPLALIH100ML Innovative research each 298 EUR

Innovative Grade US Origin Chicken Plasma

IGCHPLALIH50ML Innovative research each 185 EUR

Innovative Grade US Origin Chicken Plasma

IGCHPLANAC100ML Innovative research each 298 EUR

Innovative Grade US Origin Chicken Plasma

IGCHPLANAC50ML Innovative research each 185 EUR

Innovative Grade US Origin Chicken Plasma

IGCHPLANAE100ML Innovative research each 298 EUR

Innovative Grade US Origin Chicken Plasma

IGCHPLANAE50ML Innovative research each 185 EUR

Innovative Grade US Origin Chicken Plasma

IGCHPLANAH100ML Innovative research each 298 EUR

Innovative Grade US Origin Chicken Plasma

IGCHPLANAH50ML Innovative research each 185 EUR

Innovative Grade US Origin Chicken Gizzard

IGCHGZF Innovative research each 133 EUR

Innovative Grade US Origin Chicken Gizzard

IGCHGZP Innovative research each 210 EUR

Innovative Grade US Origin Chicken Gizzard

IGCHGZS Innovative research each 210 EUR

Innovative Grade US Origin Chicken Gizzard

IGCHGZZ Innovative research each 133 EUR

Innovative Grade US Origin Chicken Parotid

IGCHPTDF Innovative research each 133 EUR

Innovative Grade US Origin Chicken Parotid

IGCHPTDP Innovative research each 210 EUR

Innovative Grade US Origin Chicken Parotid

IGCHPTDS Innovative research each 210 EUR

Innovative Grade US Origin Chicken Parotid

IGCHPTDZ Innovative research each 133 EUR

Innovative Grade US Origin Chicken Sternum

IGCHSRF Innovative research each 133 EUR

Innovative Grade US Origin Chicken Sternum

IGCHSRP Innovative research each 210 EUR

Innovative Grade US Origin Chicken Sternum

IGCHSRS Innovative research each 210 EUR

Innovative Grade US Origin Chicken Sternum

IGCHSRZ Innovative research each 133 EUR

Innovative Grade US Origin Chicken Trachea

IGCHTCAF Innovative research each 133 EUR

Innovative Grade US Origin Chicken Trachea

IGCHTCAFT1 Innovative research each 133 EUR

Innovative Grade US Origin Chicken Trachea

IGCHTCAP Innovative research each 210 EUR

Innovative Grade US Origin Chicken Trachea

IGCHTCAPT1 Innovative research each 210 EUR

Innovative Grade US Origin Chicken Trachea

IGCHTCAS Innovative research each 210 EUR

Innovative Grade US Origin Chicken Trachea

IGCHTCAST1 Innovative research each 210 EUR

Innovative Grade US Origin Chicken Trachea

IGCHTCAZ Innovative research each 133 EUR

Innovative Grade US Origin Chicken Trachea

IGCHTCAZT1 Innovative research each 133 EUR

Innovative Grade US Origin Chicken Pancreas

IGCHPCSF Innovative research each 133 EUR

Innovative Grade US Origin Chicken Pancreas

IGCHPCSP Innovative research each 210 EUR

Innovative Grade US Origin Chicken Pancreas

IGCHPCSS Innovative research each 210 EUR

Innovative Grade US Origin Chicken Pancreas

IGCHPCSZ Innovative research each 133 EUR

Filamin Standard Grade From Chicken Gizzard

GWB-955E5F GenWay Biotech 0.25 mg Ask for price

Innovative Grade US Origin Chicken Whole Blood

IGCHWBASV100ML Innovative research each 231 EUR

Innovative Grade US Origin Chicken Whole Blood

IGCHWBASV500ML Innovative research each 700 EUR

Innovative Grade US Origin Chicken Whole Blood

IGCHWBASV50ML Innovative research each 163 EUR

Innovative Grade US Origin Chicken Whole Blood

IGCHWBK2E500ML Innovative research each 722 EUR

Innovative Grade US Origin Chicken Whole Blood

IGCHWBK2E50ML Innovative research each 163 EUR

Innovative Grade US Origin Chicken Whole Blood

IGCHWBK3E100ML Innovative research each 220 EUR

Innovative Grade US Origin Chicken Whole Blood

IGCHWBK3E500ML Innovative research each 722 EUR

Innovative Grade US Origin Chicken Whole Blood

IGCHWBK3E50ML Innovative research each 163 EUR

Innovative Grade US Origin Chicken Whole Blood

IGCHWBLIH100ML Innovative research each 231 EUR

Innovative Grade US Origin Chicken Whole Blood

IGCHWBLIH500ML Innovative research each 700 EUR

Innovative Grade US Origin Chicken Whole Blood

IGCHWBLIH50ML Innovative research each 170 EUR

Innovative Grade US Origin Chicken Whole Blood

IGCHWBNAC100ML Innovative research each 220 EUR

Innovative Grade US Origin Chicken Whole Blood

IGCHWBNAC500ML Innovative research each 722 EUR

Innovative Grade US Origin Chicken Whole Blood

IGCHWBNAC50ML Innovative research each 163 EUR

Innovative Grade US Origin Chicken Whole Blood

IGCHWBNAE100ML Innovative research each 220 EUR

Innovative Grade US Origin Chicken Whole Blood

IGCHWBNAE500ML Innovative research each 722 EUR

Innovative Grade US Origin Chicken Whole Blood

IGCHWBNAE50ML Innovative research each 163 EUR

Innovative Grade US Origin Chicken Whole Blood

IGCHWBNAH100ML Innovative research each 220 EUR

Innovative Grade US Origin Chicken Whole Blood

IGCHWBNAH500ML Innovative research each 722 EUR

Innovative Grade US Origin Chicken Whole Blood

IGCHWBNAH50ML Innovative research each 163 EUR

Innovative Grade US Origin Chicken Whole Blood

IGCNHWBK2E100ML Innovative research each 220 EUR

Collagen Type II, chicken

MBS397124-01mL MyBiosource 0.1mL 630 EUR

Collagen Type II, chicken

MBS397124-5x01mL MyBiosource 5x0.1mL 2680 EUR

Innovative Grade US Origin Chicken Gland Pituitary

IGCHGLPTF Innovative research each 133 EUR

Innovative Grade US Origin Chicken Gland Pituitary

IGCHGLPTP Innovative research each 210 EUR

Innovative Grade US Origin Chicken Gland Pituitary

IGCHGLPTS Innovative research each 210 EUR

Innovative Grade US Origin Chicken Gland Pituitary

IGCHGLPTZ Innovative research each 133 EUR

Innovative Grade US Origin Chicken Reproductive Tract

IGCHRPTCTF Innovative research each 133 EUR

Innovative Grade US Origin Chicken Reproductive Tract

IGCHRPTCTP Innovative research each 210 EUR

Innovative Grade US Origin Chicken Reproductive Tract

IGCHRPTCTS Innovative research each 210 EUR

Innovative Grade US Origin Chicken Reproductive Tract

IGCHRPTCTZ Innovative research each 133 EUR

Native Chicken Collagen Type II

NATE-1165 Creative BioMart 1 kg 263.2 EUR

Innovative Grade US Origin Chicken Intestine Small Ileum Only

IGCHINTF Innovative research each 133 EUR

Innovative Grade US Origin Chicken Intestine Small Ileum Only

IGCHINTP Innovative research each 210 EUR

Innovative Grade US Origin Chicken Intestine Small Ileum Only

IGCHINTS Innovative research each 210 EUR

Innovative Grade US Origin Chicken Intestine Small Ileum Only

IGCHINTZ Innovative research each 133 EUR

Chicken egg ovalbumin protein (ELISA Kit, antigen, allergy grade)

OVA15-N-1000 Alpha Diagnostics 1 g 489.6 EUR

Chicken Collagen Type II (COL- II) ELISA Kit

SL0173Ch Sunlong - Ask for price

T-Cell Grade Chick Type I Collagen, 0.5 mg, lyophilized

1051 Chondrex 0.5 mg 100 EUR

Chicken Collagen Type II ELISA kit

E01A89648 BlueGene 96T 700 EUR

Chicken Collagen Type II ELISA Kit

MBS016577-10x96StripWells MyBiosource 10x96-Strip-Wells 6725 EUR

La diffusione del virus della distruzione se  redujo ligeramente en el día 21 (16 days después of desafío) en el group vacunado con v301B / 1-IL-15 más HVT, sin diferencias stadísticamente significativas conspecto má con v301B e l’atrofia  del timo se que era menos severa en el grupo vuoto con v301B / 1-IL-15 más HVT. Nel complesso, la protezione della conferenza v301B/1-IL-15 non è di particolare importanza per la conferenza v301B/1 contro l’esposizione del virus Mark al virus virulento, senza intaccare il fieno grazie all’efficacia del virus Mark bivalente.

Lascia un commento

Il tuo indirizzo email non sarà pubblicato.